Rosengren et al., demonstrated that Alzheimer’s disease and amyotrophic lateral sclerosis patients have significantly higher CSF NfL levels than healthy subjects, suggesting that CSF NfL titre can be used as a biomarker of neurodegeneration [28]. Here, NEFL is linked to early-onset autosomal dominant Alzheimer disease.